<DOC>
	<DOCNO>NCT00058617</DOCNO>
	<brief_summary>Patients type lymph gland cancer call Hodgkin non-Hodgkin Lymphoma come back go away treatment , include best treatment know relapsed Lymphoma . Patients ask volunteer research study use Epstein Barr virus specific cytotoxic T lymphocytes , new experimental therapy . This therapy never use patient Hodgkin disease type non-Hodgkin Lymphoma use successfully child type blood cancer cause EBV bone marrow transplantation . Some patient Hodgkin non-Hodgkin Lymphoma show evidence infection virus cause infectious mononucleosis Epstein Barr virus time diagnosis Lymphoma . EBV often find cancer cell suggest may play role cause Lymphoma . The cancer cell infect EBV clever able hide body 's immune system escape destruction . Investigators want see 's possible grow special white blood cell , call T cell , train kill EBV infected cell . Purpose The purpose study find large safe dose EBV specific cytotoxic T cell , learn side effect see whether therapy might help patient Hodgkin disease non-Hodgkin Lymphoma .</brief_summary>
	<brief_title>Epstein Barr Virus ( EBV ) Specific Cytotoxic T-Cells , Relapsed Lymphoma , ANGEL</brief_title>
	<detailed_description>The investigator take 60-70 ml ( 12 teaspoonful ) blood patient make B cell line call lymphoblastoid cell line LCL infect blood laboratory strain EBV call B95-8 . The investigator use EBV infect cell line ( treated radiation grow ) stimulator cell mix blood . This stimulation train T cell kill EBV infect cell result growth EBV specific T cell line . The investigator test T cell make sure kill EBV infected cell normal cell freeze . Patients enter one three different dose schedule evaluate . Three six patient evaluate dose schedule . Escalation continue irreversible life threaten side effect consider related T cell see . The cell thaw injected patient ' vein 10 minute , pretreatment Tylenol Benadryl . Tylenol Benadryl give prevent possible allergic reaction T cell administration . Initially , two dos T cell give two week apart . If second infusion reduction size patient 's lymphoma CT MRI scan assess radiologist , patient receive six additional dos T cell . All treatment give Texas Children 's Hospital Methodist Hospital . Patients follow clinic injection . To learn way T cell work long last body , extra 40 ml ( 8 teaspoonful ) blood take infusion 24 hour infusion , 3-4 day infusion 1 , 2 , 4 , 6 week post infusion 3 , 6 , 9 12 month post infusion . The blood may draw central line time regular blood test . This blood use test frequency activity EBV specific T cell . A total least 122 teaspoon ( approximately 40 tablespoon ) blood collect participation study . If patient decide withdraw time study sample data collect participation maintain .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Neomycin</mesh_term>
	<criteria>INCLUSION CRITERIA : Any patient EBV positive Hodgkin disease nonHodgkin Lymphoma , plasma cell neoplasms second relapse regardless age sex , first relapse primary disease first remission immunosuppressive chemotherapy contraindicate , e.g . patient develop Hodgkin disease solid organ transplantation Lymphoma second malignancy e.g . Richters transformation CLL . Life expectancy great 6 week . No severe intercurrent infection Patient , parent/guardian able give inform consent Bilirubin &lt; 2x normal , SGOT &lt; 3x normal , Hgb great 8.0 g/L Creatinine &lt; 2x normal age Must investigational therapy one month prior entry study . Karnofsky score great equal 50 . EXCLUSION CRITERIA : Patient EBV positive NHL secondary acquire immunodeficiency . Patients HIV positive Patient , parent/guardian unable give inform consent Patients Karnofsky score &lt; 50 . Patients life expectancy &lt; 6 week Patients bilirubin great 2x normal . SGOT great 3x normal Patients creatinine great 2x normal age Due unknown effect therapy fetus , pregnant woman exclude research . The male partner use condom . Note : Patients would exclude protocol strictly laboratory abnormality include investigator 's discretion approval CCGT Protocol Review Committee FDA reviewer .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>EBV Positive Hodgkin 's Lymphoma</keyword>
	<keyword>EBV Positive Non-Hodgkin 's Lymphoma</keyword>
	<keyword>EBV Specific Cytotoxic T-Lymphocytes</keyword>
</DOC>